Boku Narikazu - Papers

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.

Takashima A, Shitara K, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Fujii H, Muro K, Esaki T, Choda Y, Takano T, Chin K, Sato A, Goto M, Fukushima N, Hara T, Machida N, Ohta M, Boku N, Shimura M, Morita S, Koizumi W

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 22(1) 155 - 163 1 2019 Peer-reviewed

Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study.

Yoshitaka Honma, Takashi Terauchi, Ukihide Tateishi, Daisuke Kano, Kengo Nagashima, Hirokazu Shoji, Satoru Iwasa, Atsuo Takashima, Ken Kato, Tetsuya Hamaguchi, Narikazu Boku, Yasuhiro Shimada, Yasuhide Yamada

The British journal of radiology 91(1089) 20180259 - 20180259 9 2018 Peer-reviewed

Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis. Cancer Chemother Pharmacol.

Iizumi S, Takashima A, Sakamaki K, Morita S, Boku N

Cancer Chemother Pharmacol. 1 2018 Peer-reviewed

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial

Yung-Jue Bang, Rui-Hua Xu, Keisho Chin, Keun-Wook Lee, Se Hoon Park, Sun Young Rha, Lin Shen, Shukui Qin, Nong Xu, Seock-Ah Im, Gershon Locker, Phil Rowe, Xiaojin Shi, Darren Hodgson, Yu-Zhen Liu, Narikazu Boku

LANCET ONCOLOGY 18(12) 1637 - 1651 12 2017 Peer-reviewed

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon-Koo Kang, Narikazu Boku, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Li-Tzong Chen

LANCET 390(10111) 2461 - 2471 12 2017 Peer-reviewed

Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study

Sakura Iizumi, Atsuo Takashima, Yukiya Narita, Masahiro Tajika, Kei Muro, Sadayuki Kawai, Hirofumi Yasui, Tomohiro Matsushima, Daisuke Takahari, Kengo Nagashima, Narikazu Boku

CANCER CHEMOTHERAPY AND PHARMACOLOGY 80(3) 575 - 582 9 2017 Peer-reviewed

Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials

Daisuke Takahari, Junki Mizusawa, Wasaburo Koizumi, Ichinosuke Hyodo, Narikazu Boku

GASTRIC CANCER 20(5) 757 - 763 9 2017 Peer-reviewed

Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world

Atsuo Takashima, Sakura Iizumi, Narikazu Boku

JAPANESE JOURNAL OF CLINICAL ONCOLOGY 47(7) 583 - 589 7 2017 Peer-reviewed

Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes

Takashi Nishimura, Satoru Iwasa, Kengo Nagashima, Natsuko Okita, Atsuo Takashima, Yoshitaka Honma, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada, Narikazu Boku

GASTRIC CANCER 20(4) 655 - 662 7 2017 Peer-reviewed